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In this issue of Dicihctologia,  Pickkers el al. have put (KATP) channels these tissue differences are well- 
forward an interesting hypothesis on the cellular known. The KAT1, channel opener and experimental 
mechanism of action of thiazide-induced hypergly- 
caemia. In the past few years, these investigators 
have documented convincingly that the vusorelaxing 
properties of thiazide diuretics can he explained by 
opening of calcium-activated potassium (Kt-„) chan­
nels in vascular smooth muscle cells. Since these par­
ticular potassium channels also occur in pancreatic 
beta cells, they reason that thiazides are expected to 
hyperpolarize the pancreatic beta cell with subse­
quent closure of the voltage-dependent calcium chan­
nel. This mechanism could explain the fall in intracel­
lular calcium and, as a consequence, reduction in in­
sulin release as previousyl reported by Sandström [ 1 ].
The hypothesis of Pickkers el al. is primarily based 
on in vitro observations of the effects of thiazides on 
vascular smooth muscle cells. Actually, they extrapo­
late findings on the acute effects of thiazide diuretics 
on vascular smooth muscle cells in vitro to the chron-
vasodilator drug levcromakalim for example is highly 
effective at the level of the smooth muscle cells, but is 
hardly able to open pancreatic KATP channels [3]. As 
a consequence, this experimental drug will not result 
in inhibition of insulin secretion at therapeutic con­
centrations, whereas these concentrations will give 
rise to a potent vasodilator response. Apparently, 
this experimental drug can be classified as a vascular 
selective K/Vn. channel opener. It is important to real­
ize that in the hypothesis of Pickkers et al., the au­
thors assume that thiazide diuretics will act as non-se- 
lective Kr., openers.
A  rise in intracellular calcium concentration is the 
final common pathway in the stimulus-secrelion cou­
pling of insulin in pancreatic beta cells [4]. Apart 
from uptake and release from intracellular calcium 
stores, intracellular calcium concentration is depen­
dent on the influx of calcium through voltage oper-
ic exposure of pancreatic cells to thiazides in vivo. Of ated calcium channels, The key role of calcium in the 
course, this must be interpreted with caution because exocytosis of insulin-containing secretory granules is 
there are no data to show that the hyperpolarizing re- emphasized in experiments with calcium entry block-
sponse to thiazides persists during long-term expo­
sure. In this regard it is also interesting to realize 
that the acute and direct vasodilator properties of thi­
azides could not be reproduced in an in vivo setting in 
humans [2|. Moreover, the K(il channels of the
ers. In the isolated rat pancreas, insulin release was 
inhibited by verapamil [5], a potent calcium entry 
blocker known to inhibit excitation-contraction cou­
pling in both myocardial and vascular smooth muscle 
cells. Insulin secretion was also found to be slightly
smooth muscle cells and of pancreatic beta cells may reduced in patients with required treatment with the 
belong to the same family, but this does not exclude dihydroperidine derivative nifedipine [6], However, 
important tissue differences in channel characteris- in clinical practice the diabetogenic effect of calcium 
tics. For the so-called ATP-dependent potassium entry blockers appears to be small [7].
The open state probability of voltage operated cal­
cium channels is also highly dependent on the mem­
brane potential. Since the membrane potential is 
mainly regulated by the opening and closure of potas­
sium channels, insulin secretion of the beta cell may 
be significantly modulated by substances interfering 
with pancreatic potassium channels. As such, the
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Fig. 1. Schematic representation of the pancreatic beta ce ll  
Outline of potential effects of endogenous and exogenous sub­
stances that open ATP-dependent (KATP) or calcium-activated 
(KCa) potassium channels. Opening of potassium channels 
results in potassium efflux, and subsequent hyperpolarization. 
This hyperpolarization closes voltage operated calcium chan­
nels, thereby reducing intracellular calcium ([Ca2+]i) and
related insulin release. Some of the agents are assumed to bind 
directly to the potassium channel (for example the diabetoge­
nic drug diazoxide), whereas others are thought to act via stim­
ulation of specific receptors coupled to the channel (for exam­
ple adenosine via the A t adenosine receptor). © Positive stimu­
lation; in case of channels this is similar to opening; © Inhibi­
tion; in case of channels, this is similar to closing
mechanisms of action of thiazide diuretics suggested by almost 50 % [11]. Up to now, the cellular mode of
by Pickkers et al. may be relevant to all kinds of sub- action of this CGRP-effect is not clear, but the puta-
stances which interact with potassium channels and live interaction with pancreatic potassium channels
or alter membrane potential. Apart from a variety of warrants further attention. Interestingly, the chemical
drugs, several endogenous substances can also inter- structure of CGRP shows striking similarity with that
fere with pancreatic potassium channels. Figure 1 is of islet amylin polypeptide (IAPP). In patients with
a schematic representation of the effect of potassium non-insulin-dependent diabetes mellitus IAPP con-
channel opening on the pancreatic beta cell. centrations are increased and are reported to conlrib-
A  striking example of an endogenous potasium ute to the impaired secretion of insulin [12]. In this re­
channel opener is somatostatin. Somatostatin is a 
well-known and potent inhibitor of insulin secretion,
gard it is tempting to speculate that the cellular mech­
anism of action of the IAPP-induced reduction in in­
an d is used for this purpose in humans as a tool to sulin release is based on opening of KAT1. channels in 
block insulin secretion in experimental conditions the pancreatic beta cells. As such, sulphonylurea de- 
and to treat insulinoma-associated hypoglycaemia. rivatives may be expected to be more potent in pa- 
This peptide has been shown to hyperpolarize the tients with high IAPP concentrations in the pancreas, 
membrane by opening of KAT1> channels [8], and The polypeptide galanin is also able to hyperpolarize 
therefore illustrates the importance of the control of cell membranes by opening of KATI. channel. Both in 
membrane potential in pancreatic insulin release. vivo and in the isolated perfused pancreas, galanin 
Similar mechanisms may be relevant to galanin and abolished insulin secretion [13-151.
calcitonin gene related peptide (CGRP). Indeed, 
CGRP is a potent vasodilator substance in several or-
In contrast to the extensive knowledge on the 
modulation of KATI> channels, data on the effects of 
gan systems, including the human skeletal muscle vas- endogenous or pharmacological agents on the open 
cular bed [9], Experiments with the sulphonylurea probability of K0l channels are scarce. Recently, 
derivative glibenclamide, a well-known blocker of White et al. [16] observed that oestrogens are able to 
KAtp channels, have shown that CGRP exerts its ef- open KCa channels in smooth muscle cells. In their in 
fects at least in part by opening of KATP channels vitro preparation, oestradiol showed a vasorelaxant 
[10], Direct infusion of CGRP into the pancreatic effect which was inhibited by the highly selective 
artery is able to inhibit glucose-induced insulin release K Ca channel blocker charybdotoxin. In line with the
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hypothesis of Pickkers e l al. this potassium channel 
opening properly of oestrogens may offer a cellular 
mechanism to explain the observed direct inhibiting 
effect o f this sex horm one on pancreatic insulin re­
lease [17]. Up to now, there appear to be no pharma­
cological agents which selectively interact with K CiX 
channels. For this reason, the observation that thiaz­
ide diuretics open this channel in sm ooth muscle cells 
and possibly also in the pancreatic beta cells make 
this class of drugs of special interest.
From these data it is obvious that modulation of 
the open probability of potassium channels at the le­
vel of the pancreatic beta cells is of major importance 
with respect to insulin secretion. It has lo be em pha­
sized lhal the diabetogenic mechanism o f action of a 
wide variety of substances has not been elucidated. 
Therefore, all drugs or endogenous hormones that af­
fect glucose metabolism should be investigated on 
their ability to interact with potassium channels. B e­
cause of the availability of highly selective blockers 
of the various potassium channels, these investiga­
tions are relatively easy to perform in an in vitro 
preparation. The patch clamp technique even enables 
these kinds of investigations at a cellular or single 
channel level. It will be much more complicated to 
determine whether these proposed mechanisms of 
action are also of significance in the in vivo situation.
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